Anthony Rendon stealing second

Washington Nationals third baseman Anthony Rendon steals second base in a game against the New York Mets, 18 May 2014. More photography by Alan Kotok

Technology News and Literature provides quality news reporting on the intersection of science, technology, business, and public policy. This site provides links to current and previous work, including online services, books, articles, white papers, and photography.

Recent work online and in print

  • Seeking Alpha. Shire Acquisition Bolsters Its Rare, And Maybe Not-So-Rare, Disease Portfolio. 19 May 2014. The acquisition by Shire plc earlier this month of Lumena Pharmaceuticals builds Shire's already strong position in rare diseases, but the acquisition can also help Shire advance drug development programs aimed at larger populations.
  • LinkedIn. My Mission: Journalists Who Love Math. 26 April 2014. For too many reporters of all kinds, covering a story with any amount of quantification seems to make them surrender to the words in a press release. I'm on a mission to change that.
  • Seeking Alpha. New GlaxoSmithKline Diabetes Drug Needs Innovative Marketing Strategy. 21 April 2014. A diabetes drug approved last week for sale in the U.S. and Europe brings GlaxoSmithKline (GSK) into a new therapy field for the company, one that is both crowded and changing rapidly with the ageing of baby boomers and new directions in health care.
  • Seeking Alpha. Myriad Genetics' Acquisition Of Crescendo Bioscience: A Question Of Timing. 10 February 2014. "At first glance, the acquisition makes a lot of sense for Myriad, adding a ready-made capability in a complementary line, but also this week, the scientific landscape changed markedly for rheumatoid arthritis and similar disorders, adding a wrinkle into Myriad's plans for the company."
  • Seeking Alpha. Bayer's Curious Acquisition Of Cancer Drug Maker Algeta. 23 December 2013. News of the acquisition stressed Bayer's getting "outright control" of Algeta's drug for advanced prostate cancer through the acquisition, but a look at Algeta's technology suggests Bayer is getting more for its $2.9 billion than a single drug it already markets.
  • Seeking Alpha. Walgreen's Mobile Strategy Scores With Retail Customers. 30 July 2013. Walgreen's mobile strategy is paying off in higher sales volume for mobile customers than store-only customers, but wellness apps are a different world for a company that's still essentially a drug store chain.
  • Seeking Alpha. New GlaxoSmithKline Diabetes Drug Needs Innovative Marketing Strategy. 21 April 2014. A diabetes drug approved last week for sale in the U.S. and Europe brings GlaxoSmithKline (GSK) into a new therapy field for the company, one that is both crowded and changing rapidly with the ageing of baby boomers and new directions in health care.
  • Seeking Alpha. Celgene Expanding R&D Portfolio Into Regenerative Medicine. 8 July 2013. Biopharmaceutical company Celgene Corporation is venturing beyond its biologic therapy pipeline into tissue engineering and regenerative medicine in a series of deals with the biotech Tengion Inc.
  • Seeking Alpha. Stratasys Prepares For 3-D Synthetic Biomaterials. 24 June 2013. Enterprise 3-D printer developer Stratasys made headlines with its acquisition of MakerBot, but in that same week the company collaborated with an MIT research group that used 3-D printing to create synthetic bone matter from a complex computer model.
  • Seeking Alpha. St. Jude Medical Boosts Anti-Pain Portfolio In $40M Deal. 9 June 2013. Medical technology company St. Jude Medical bought a piece of pain management system developer Spinal Modulation and got an exclusive license to market its innovative neurostimulation device worldwide.
  • Seeking Alpha. Clearing The Air On The Sanofi-Regeneron Asthma Drug Trial. 28 May 2013. While the findings of a clinical trial testing a new asthma drug by Sanofi and Regeneron Pharmaceuticals are medically and financially promising, the science behind the study suggests some limitations, yet also other opportunities for the drug.
  • Seeking Alpha. Shire's New Rare Disease Deal: Interesting Science Meets Unique Financing. 13 May 2013. The biotechnology company Nimbus Discovery announced an agreement with the specialty pharmaceutical developer Shire plc that combines an innovative technology for drug discovery with a novel financing method to move that technology forward.
  • E-book: Cienfuegos Rainbow: Observations of a 21st Century Cuba. April 2013. An eight-day study tour of Cuba became an eye-opening experience that highlighted a country struggling to feed and house its population in the 21st century, while stuck in a confrontational cold war past. Alan and Sharon Kotok describe their experiences as part of a group of University of Iowa alumni who visited Cuba in January 2013.

About Alan Kotok

Alan Kotok is a Washington, DC-based reporter and writer on technology, business, and public policy, and editor and publisher of Science and Enterprise, an online news service on the value chain connecting scientific discovery with the marketplace. Kotok previously was managing editor of Science Careers, the online employment, career development, and funding portal of Science Magazine. Alan also serves as editor of PublicDiplomacy.org, the Web site of the Public Diplomacy Alumni Association. More details are available inside.

Alan Kotok
Technology News and Literature
4521 N. 41st Street
Arlington, Virginia, 22207 USA

This hCard created with the hCard creator | Download electronic business card (vcard).